Peter J Weiden

Summary

Publications

  1. ncbi request reprint Obesity as a risk factor for antipsychotic noncompliance
    Peter J Weiden
    SUNY Health Sciences Center at Brooklyn, Brooklyn, NY 11203 2098, USA
    Schizophr Res 66:51-7. 2004
  2. ncbi request reprint Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
    Peter J Weiden
    Department of Psychiatry, Box 1203, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Clin Psychopharmacol 23:595-600. 2003
  3. ncbi request reprint Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications
    Peter J Weiden
    Department of Psychiatry, State University of New York SUNY Downstate Medical Center, Brooklyn, NY, USA
    J Clin Psychiatry 68:14-23. 2007
  4. ncbi request reprint Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia
    Peter J Weiden
    State University of New York SUNY Downstate Medical Center and King s County Hospital, Brooklyn, N Y, USA
    J Clin Psychiatry 68:34-9. 2007
  5. ncbi request reprint The art and science of switching antipsychotic medications, part 2
    Peter J Weiden
    Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, USA
    J Clin Psychiatry 68:e02. 2007
  6. ncbi request reprint The art and science of switching of antipsychotic medications, part 1
    Peter J Weiden
    Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center, Brooklyn, USA
    J Clin Psychiatry 67:e15. 2006
  7. ncbi request reprint Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia
    Peter J Weiden
    Department of Psychiatry, SUNY Downstate Medical Center State, Brooklyn, NY 11203, USA
    J Clin Psychiatry 64:580-8. 2003
  8. ncbi request reprint Switching antipsychotics: an updated review with a focus on quetiapine
    Peter J Weiden
    Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Psychopharmacol 20:104-18. 2006
  9. ncbi request reprint Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
  10. ncbi request reprint Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
    George M Simpson
    Department of Psychiatry and the Behavioral Sciences, LAC USC Medical Center, IRD RM 204, Psychiatric Outpatient Clinic, 2020 Zonal Ave, Los Angeles, CA 90033, USA
    Am J Psychiatry 161:1837-47. 2004

Detail Information

Publications26

  1. ncbi request reprint Obesity as a risk factor for antipsychotic noncompliance
    Peter J Weiden
    SUNY Health Sciences Center at Brooklyn, Brooklyn, NY 11203 2098, USA
    Schizophr Res 66:51-7. 2004
    ..It is, therefore, increasingly important to understand the impact of obesity and perceived weight problems on compliance with these medications...
  2. ncbi request reprint Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
    Peter J Weiden
    Department of Psychiatry, Box 1203, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Clin Psychopharmacol 23:595-600. 2003
    ....
  3. ncbi request reprint Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications
    Peter J Weiden
    Department of Psychiatry, State University of New York SUNY Downstate Medical Center, Brooklyn, NY, USA
    J Clin Psychiatry 68:14-23. 2007
    ..The authors explain how to evaluate the specific side effect in the context of the current medication and the overall management of the patient...
  4. ncbi request reprint Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia
    Peter J Weiden
    State University of New York SUNY Downstate Medical Center and King s County Hospital, Brooklyn, N Y, USA
    J Clin Psychiatry 68:34-9. 2007
    ....
  5. ncbi request reprint The art and science of switching antipsychotic medications, part 2
    Peter J Weiden
    Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, USA
    J Clin Psychiatry 68:e02. 2007
    ....
  6. ncbi request reprint The art and science of switching of antipsychotic medications, part 1
    Peter J Weiden
    Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center, Brooklyn, USA
    J Clin Psychiatry 67:e15. 2006
    ....
  7. ncbi request reprint Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia
    Peter J Weiden
    Department of Psychiatry, SUNY Downstate Medical Center State, Brooklyn, NY 11203, USA
    J Clin Psychiatry 64:580-8. 2003
    ....
  8. ncbi request reprint Switching antipsychotics: an updated review with a focus on quetiapine
    Peter J Weiden
    Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Psychopharmacol 20:104-18. 2006
    ..Finally, advice is provided on the assessments necessary when evaluating the success of a change in therapy, together with guidance on the optimal duration of treatment trials...
  9. ncbi request reprint Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
    ..Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects...
  10. ncbi request reprint Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
    George M Simpson
    Department of Psychiatry and the Behavioral Sciences, LAC USC Medical Center, IRD RM 204, Psychiatric Outpatient Clinic, 2020 Zonal Ave, Los Angeles, CA 90033, USA
    Am J Psychiatry 161:1837-47. 2004
    ..The authors compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely ill inpatients with schizophrenia or schizoaffective disorder...
  11. ncbi request reprint Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning
    David L Ginsberg
    Georgetown University School of Medicine, USA
    CNS Spectr 10:1-13; discussion 14-15. 2005
    ..Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments...
  12. ncbi request reprint Understanding and addressing adherence issues in schizophrenia: from theory to practice
    Peter J Weiden
    Center for Cognitive Medicine, Department of Psychiatry, University of Illinois, Chicago 60612, USA
    J Clin Psychiatry 68:14-9. 2007
    ..5) Adherence behavior changes and fluctuates over time and should be considered as part of the illness in the context of the long-term trajectory of desired clinical outcomes such as recovery...
  13. ncbi request reprint Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
    ..To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone...
  14. ncbi request reprint Cognitive behavior therapy for schizophrenia
    Douglas Turkington
    Department of Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear NE4 4LP, UK
    Am J Psychiatry 163:365-73. 2006
    ..The objective of this article is to offer a broad perspective on the subject of cognitive behavior therapy for schizophrenia for the American reader...
  15. ncbi request reprint Understanding and treating "first-episode" schizophrenia
    Peter J Weiden
    Department of Psychiatry, University of Illinois Medical Center, Chicago, IL, USA
    Psychiatr Clin North Am 30:481-510. 2007
    ..Clinicians and treatment services should try to identify "first-episode" patients in time to be able to anticipate and address these issues...
  16. ncbi request reprint Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap
    Peter J Weiden
    University of Illinois at Chicago, USA
    J Clin Psychiatry 68:1-48. 2007
    ....
  17. doi request reprint Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia
    Andrew J Cutler
    University of Florida, Gainesville, FL, USA
    J Clin Psychopharmacol 28:S20-8. 2008
    ..Overall, there was improvement in akathisia with iloperidone treatment. Iloperidone treatment was effective, safe, and well tolerated in patients with acute exacerbation of schizophrenia...
  18. doi request reprint Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials
    Peter J Weiden
    Center for Cognitive Medicine, Chicago, IL 60612, USA
    J Clin Psychopharmacol 28:S12-9. 2008
    ....
  19. ncbi request reprint Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
    ..These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids...
  20. ncbi request reprint Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial
    Peter J Weiden
    Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn 11203, USA
    J Clin Psychiatry 68:12-9. 2007
    ..Therefore, the clinical implications of the CATIE phase 1 findings may depend, in part, on the underlying assumptions of the ACD outcome measure...
  21. ncbi request reprint EPS profiles: the atypical antipsychotics are not all the same
    Peter J Weiden
    Dept of Psychiatry, SUNY Downstate Medical Center in Brooklyn, NY 11203, USA
    J Psychiatr Pract 13:13-24. 2007
    ..This review discusses differences among the SGAs in EPS liability, relationships between dosing and type of EPS, and situations in which differences in EPS liability among the SGAs are clinically relevant...
  22. ncbi request reprint Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications
    Patricia L Scheifler
    Partnership for Recovery, Sylacauga, AL 35150, USA
    Postgrad Med . 2006
    ..It is also important to revisit the initial treatment goals to distinguish primary pharmacologic improvements from secondary psychologic reactions and challenges arising from those improvements...
  23. ncbi request reprint Switching in the era of atypical antipsychotics. An updated review
    Peter J Weiden
    Department of Psychiatry, State University of New York, Downstate Medical Center Brooklyn, NY 11203, USA
    Postgrad Med . 2006
    ....
  24. ncbi request reprint From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  25. ncbi request reprint Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia
    Peter J Weiden
    State University of New York in Brooklyn, USA
    Psychiatr Serv 55:886-91. 2004
    ..The objective of this study was to evaluate the relationship between compliance with an antipsychotic medication regimen and risk of hospitalization in a cohort of California Medicaid patients with schizophrenia...
  26. doi request reprint Antipsychotic-induced movement disorders - forgotten but not gone
    Peter J Weiden
    Acta Psychiatr Scand 117:401-2. 2008